0000000000420743

AUTHOR

Matthias W. Beckmann

showing 14 related works from this author

Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen

2009

Context The growth inhibitory effect of tamoxifen, which is used for the treatment of hormone receptor–positive breast cancer, is mediated by its metabolites, 4-hydroxytamoxifen and endoxifen. The formation of active metabolites is catalyzed by the polymorphic cytochrome P450 2D6 (CYP2D6) enzyme. Objective To determine whether CYP2D6 variation is associated with clinical outcomes in women receiving adjuvant tamoxifen. Design, Setting, and Patients Retrospective analysis of German and US cohorts of patients treated with adjuvant tamoxifen for early stage breast cancer. The 1325 patients had diagnoses between 1986 and 2005 of stage I through III breast cancer and were mainly postmenopausal (9…

Oncologymedicine.medical_specialtyAntineoplastic Agents HormonalGenotypeBreast NeoplasmsArticleBreast cancerInternal medicinemedicineHumansskin and connective tissue diseasesSurvival analysisProportional Hazards ModelsPolymorphism GeneticProportional hazards modelbusiness.industryHazard ratioCancerGeneral Medicinemedicine.diseaseAntiestrogenSurvival AnalysisTamoxifenPhenotypeTreatment OutcomeEndocrinologyCytochrome P-450 CYP2D6PharmacogeneticsFemaleBreast diseasebusinessTamoxifenmedicine.drug
researchProduct

Chylous ascites after lymphadenectomy for gynecological malignancies

2016

Background and Objectives Chylous ascites, an accumulation of milky-white lymph fluid in the peritoneal cavity, is a rare complication following retroperitoneal lymphadenectomy. This study evaluated the appearance and management of chylous ascites following lymphadenectomy for gynecological malignancies. Methods A total of 931 patients who underwent lymphadenectomy for gynecological malignancies at Erlangen University Hospital between 2002 and 2013 were reviewed retrospectively. Results Chylous ascites occurred postoperatively in 28 of the 931 patients (3.0%). All patients with chylous ascites had undergone combined systematic para-aortic and pelvic lymphadenectomy (SAPL). Patients with chy…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentRetrospective cohort studyGeneral Medicinemedicine.diseaseSurgery03 medical and health sciencesPeritoneal cavity0302 clinical medicinemedicine.anatomical_structureOncology030220 oncology & carcinogenesisChylous ascitesCarcinomamedicine030211 gastroenterology & hepatologySurgeryLymphadenectomyLymphComplicationbusinessLaparoscopyJournal of Surgical Oncology
researchProduct

Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer: AGO Uterus-4.

2006

Abstract Objective The aim of this phase II multicenter study was to evaluate the safety, toxicity and efficacy of docetaxel administered weekly as first line chemotherapy in patients with recurrent or metastatic endometrial cancer. Patients and methods Thirty five patients with recurrent or metastatic endometrial cancer without previous chemotherapy were enrolled to receive three 6-week cycles of docetaxel 35 mg/m 2 /week with 2-week breaks between the cycles. Therapy response was evaluated after every 6-week cycle, and therapy was continued in case of at least stable disease. Final therapy response was evaluated after three 6-week cycles of docetaxel. Results Thirty five patients with a m…

OncologyAdultmedicine.medical_specialtymedicine.medical_treatmentPhases of clinical researchAntineoplastic AgentsDocetaxelDrug Administration Schedule03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansNeoplasm MetastasisInfusions Intravenous030304 developmental biologyAgedAged 80 and over0303 health sciencesChemotherapybusiness.industryEndometrial cancerObstetrics and GynecologyCancerCombination chemotherapyMiddle Agedmedicine.disease3. Good healthEndometrial NeoplasmsClinical trialOncologyDocetaxel030220 oncology & carcinogenesisToxicityFemaleTaxoidsNeoplasm Recurrence Localbusinessmedicine.drugGynecologic oncology
researchProduct

Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients

2019

One of the most common adverse events (AEs) occurring during treatment with aromatase inhibitors (AIs) is musculoskeletal pain. The aim of our study was to analyze the influence of preexisting muscle/limb pain and joint pain on the development of AI-induced musculoskeletal AEs. Women eligible for upfront adjuvant endocrine therapy with letrozole were included in the PreFace study, a multicenter phase IV trial. During the first treatment year, they were asked to record musculoskeletal AEs monthly by answering questions regarding pain symptoms and rating the pain intensity on a numeric rating scale from 0 (no pain) to 10 (very strong pain). Pain values were compared using nonparametric statis…

Cancer Researchmedicine.medical_specialtyTime Factorsmedicine.drug_classMedizinBreast Neoplasms03 medical and health sciences0302 clinical medicineBreast cancerMusculoskeletal PainInternal medicinemedicineHumansIn patientAdverse effectAgedPain MeasurementEarly breast cancerAromatase inhibitorAromatase Inhibitorsbusiness.industryLetrozoleSignificant differenceMiddle Agedmedicine.diseaseArthralgiaPostmenopauseOncology030220 oncology & carcinogenesisJoint painLetrozoleFemalemedicine.symptombusinessmedicine.drugInternational Journal of Cancer
researchProduct

Gonadal damage and options for fertility preservation in female and male cancer survivors.

2006

It is estimated that in 2010, 1 in every 250 adults will be a childhood cancer survivor. Today, oncological surgery, radiotherapy and chemotherapy achieve relatively high rates of remission and long-term survival, yet are often detrimental to fertility. Quality of life is increasingly important to long-term survivors of cancer, and one of the major quality-of-life issues is the ability to produce and raise normal children. Developments in the near future in the emerging field of fertility preservation in cancer survivors promise to be very exciting. This article reviews the published literature, discusses the effects of cancer treatment on fertility and presents the options available today …

InfertilityAdultMalemedicine.medical_specialtyUrologymedicine.medical_treatmentmedia_common.quotation_subjectFertilityMale infertilityQuality of lifeTesticular NeoplasmsNeoplasmsTestismedicineHumansFertility preservationSurvivorsIntensive care medicineChildmedia_commonGynecologyOvarian NeoplasmsIn vitro fertilisationbusiness.industryOvaryCancerGeneral Medicinemedicine.diseasehumanitiesRadiation therapyFertilityInfertilityFemalebusinessAsian journal of andrology
researchProduct

Pretreatment with gonadotropin-releasing hormone (GnRH) antagonists to prevent the flare-up effect of long-acting GnRH agonists: results of a pilot s…

2007

This study evaluated in vivo whether the flare-up effect of GnRH agonists can be suppressed through pretreatment with a GnRH antagonist. The classic flare-up effect caused by 3.8 mg goserelin acetate could not be suppressed through pretreatment using a single dosage of 3.24 mg cetrorelix acetate.

AgonistMaleendocrine systemmedicine.medical_specialtyTime Factorsmedicine.drug_classPilot ProjectsGonadotropin-releasing hormoneGonadotropin-Releasing HormoneHormone AntagonistsIn vivoInternal medicinemedicineFlare upHumansTestosteroneEstradiolbusiness.industryGoserelin AcetateAntagonistObstetrics and GynecologyLuteinizing HormoneLong actingEndocrinologyTreatment OutcomeReproductive MedicineCetrorelixGoserelinFemaleFollicle Stimulating Hormone Humanbusinesshormones hormone substitutes and hormone antagonistsTranssexualismmedicine.drugFertility and sterility
researchProduct

CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.

2013

The International Tamoxifen Pharmacogenomics Consortium was established to address the controversy regarding cytochrome P450 2D6 (CYP2D6) status and clinical outcomes in tamoxifen therapy. We performed a meta-analysis on data from 4,973 tamoxifen-treated patients (12 globally distributed sites). Using strict eligibility requirements (postmenopausal women with estrogen receptor-positive breast cancer, receiving 20 mg/day tamoxifen for 5 years, criterion 1); CYP2D6 poor metabolizer status was associated with poorer invasive disease-free survival (IDFS: hazard ratio = 1.25; 95% confidence interval = 1.06, 1.47; P = 0.009). However, CYP2D6 status was not statistically significant when tamoxifen…

Oncologymedicine.medical_specialtyAntineoplastic Agents HormonalGenotypeBreast Neoplasms030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicineBreast cancerInternal medicinemedicineHumansPharmacology (medical)skin and connective tissue diseasesProspective cohort studySurvival analysisAgedPharmacologyGynecologybusiness.industryHazard ratioGenetic VariationMiddle Agedmedicine.diseaseSurvival AnalysisConfidence interval3. Good healthTamoxifenTreatment OutcomeCytochrome P-450 CYP2D6Pharmacogenetics030220 oncology & carcinogenesisMeta-analysisFemaleMenopausebusinessTamoxifenPharmacogeneticsmedicine.drugClinical pharmacology and therapeutics
researchProduct

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

2013

Journal article TERT-locus SNPs and leukocyte telomere measures are reportedly associated with risks of multiple cancers. Using the Illumina custom genotyping array iCOGs, we analyzed ~480 SNPs at the TERT locus in breast (n = 103,991), ovarian (n = 39,774) and BRCA1 mutation carrier (n = 11,705) cancer cases and controls. Leukocyte telomere measurements were also available for 53,724 participants. Most associations cluster into three independent peaks. The minor allele at the peak 1 SNP rs2736108 associates with longer telomeres (P = 5.8 × 10!-7), lower risks for estrogen receptor (ER)-negative (P = 1.0 × 10!-8) and BRCA1 mutation carrier (P = 1.1 × 10!-5) breast cancers and altered promot…

TelomeraseMessengerCàncer d'ovariEstrogen receptorAetiology screening and detection [ONCOL 5]0302 clinical medicineBreast cancerRisk FactorsAlternative Splicing; Biomarkers Tumor; Breast Neoplasms; Case-Control Studies; Chromatin; DNA Methylation; Female; Gene Expression Profiling; Genetic Loci; Genetic Predisposition to Disease; Genome-Wide Association Study; Genotype; Humans; Luciferases; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Polymorphism Single Nucleotide; RNA Messenger; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Telomerase; Telomere; GeneticsGenotypeBUCCAL CELLSLuciferasesTelomeraseOligonucleotide Array Sequence AnalysisOvarian Neoplasms0303 health sciencesTumorTelòmerReverse Transcriptase Polymerase Chain ReactionGENETIC-VARIATIONCOMMON VARIANTSSingle Nucleotidetert-clptm1l locus; genome-wide association; genetic-variation; susceptibility loci; buccal cells; fibroblasts; common variants; carcinoma; reverse-transcriptase htert; metaanalysisTelomereAetiology screening and detection Immune Regulation [ONCOL 5]Chromatin3. Good healthTumor Markers Biological030220 oncology & carcinogenesisFemaleFIBROBLASTSGenotypeSUSCEPTIBILITY LOCICARCINOMASingle-nucleotide polymorphismBreast NeoplasmsBiologyReal-Time Polymerase Chain ReactionPolymorphism Single NucleotideArticleCàncer de mama03 medical and health sciencesBreast cancerSDG 3 - Good Health and Well-beingTranslational research [ONCOL 3]Ovarian cancermedicineGeneticsBiomarkers TumorHumansGenetic Predisposition to DiseaseRNA MessengerPolymorphismAlleleGENOME-WIDE ASSOCIATIONMETAANALYSIS030304 developmental biologyMolecular epidemiology Aetiology screening and detection [NCEBP 1]Breast cancer susceptibilityHereditary cancer and cancer-related syndromes [ONCOL 1]Translational research Genomic disorders and inherited multi-system disorders [ONCOL 3]Gene Expression ProfilingDNA Methylationmedicine.diseaseMolecular biologyTERT-CLPTM1L LOCUSTelomereMinor allele frequencyAlternative SplicingGenetic LociCase-Control StudiesRNABiomarkersREVERSE-TRANSCRIPTASE HTERTGenome-Wide Association StudyNature genetics
researchProduct

Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032…

2018

Geburtshilfe und Frauenheilkunde 78(11), 1056-1088 (2018). doi:10.1055/a-0646-4630

medicine.medical_specialtyAdvanced breastPsychological interventionGuideline/LeitlinieSystemic therapymetastasiertes Mammakarzinomprimary breast cancer03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerMaternity and MidwiferyBrustkrebsMedicineprimäres Mammakarzinom030212 general & internal medicineGebFra ScienceIntensive care medicineLeitlinietherapybusiness.industryTumor biologyObstetrics and GynecologyCancerGuidelinemedicine.diseaseMetastatic breast cancerddc:030220 oncology & carcinogenesismetastatic breast cancerbusinessTherapieguideline
researchProduct

The extracorporeal perfusion of the female pig detrusor as an experimental model for the study of bladder contractility.

2007

Aims The objective of the study was to establish an experimental model for the extracorporeal perfusion of the pig detrusor. In order to validate this model we examined some biochemical parameters and determined the effect of carbachol on the contractility of perfused female pig bladders. Methods Twenty-six pig bladders were perfused with Krebs–Ringer bicarbonate-glucose buffer for a period up to 5 hr with the aim to preserve a viable organ, which would be responsive to contraction-inducing agents. The intravesical pressure of the bladder as well as the intraarterial pressure of the vesical arteries were recorded before and after administration of carbachol. Results The perfusate pH, lactat…

CarbacholUrologySus scrofaUrinary BladderPig bladderBlood PressureCholinergic AgonistsContractilitymedicineAnimalsDose-Response Relationship Drugbusiness.industryExperimental modelMuscle SmoothExtracorporeal perfusionDose–response relationshipmedicine.anatomical_structureAnesthesiaModels AnimalCarbacholFemaleNeurology (clinical)Vesical arteriesbusinessPerfusionmedicine.drugMuscle ContractionNeurourology and urodynamics
researchProduct

Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032…

2018

62. Kongress der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe, DGGG'18, Berlin, Germany, 31 Oct 2018 - 3 Nov 2018; Geburtshilfe und Frauenheilkunde 78(10), 927-948 (2018). doi:10.1055/a-0646-4522 special issue: "62. Kongress der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe, DGGG'18, Berlin, 31.10 – 03.11.2018 : Frauenheilkunde im Fokus: wissenschaftlich fundiert und der Qualität verpflichtet"

medicine.medical_specialtydiagnosisPsychological interventionComputed tomographyDiseaseGuideline/LeitlinieMammakarzinom03 medical and health sciencesbreast cancerDiagnostik0302 clinical medicineBreast cancerMaternity and Midwiferyfollow-upmedicineMammographyMedical physicsGebFra Science030212 general & internal medicinemedicine.diagnostic_testbusiness.industryscreeningObstetrics and GynecologyCancerGuidelinemedicine.diseaseddc:030220 oncology & carcinogenesisFrüherkennungRichtlinieNachsorgebusinessguidelineSystematic searchGeburtshilfe und Frauenheilkunde
researchProduct

Genome-wide association studies identify four ER negative-specific breast cancer risk loci

2013

Estrogen receptor (ER)-negative tumors represent 20-30% of all breast cancers, with a higher proportion occurring in younger women and women of African ancestry. The etiology and clinical behavior of ER-negative tumors are different from those of tumors expressing ER (ER positive), including differences in genetic predisposition. To identify susceptibility loci specific to ER-negative disease, we combined in a metaanalysis 3 genome-wide association studies of 4,193 ER-negative breast cancer cases and 35,194 controls with a series of 40 follow-up studies (6,514 cases and 41,455 controls), genotyped using a custom Illumina array, iCOGS, developed by the Collaborative Oncological Gene-environm…

Oncologygenetic associationbody-mass indexEstrogen receptorGenome-wide association studycancer riskBioinformaticssusceptibilitychromosome 1q0302 clinical medicineRisk Factorssingle nucleotide polymorphismGenotypeestrogenCooperative Behaviorcomparative studyOligonucleotide Array Sequence Analysis0303 health scienceschromosome 16q3. Good healthReceptors Estrogenpriority journal030220 oncology & carcinogenesisFemalecancer invasionsignal transductionbreast cancer; cancer invasion; cancer risk; chromosome 1; chromosome 16q; chromosome 1q; chromosome 2p; comparative study; follow up; gene locus; genetic association; genetic susceptibility; human; nucleotide sequence; priority journal; signal transduction; single nucleotide polymorphismmedicine.medical_specialtyGenotypegene locusBreast NeoplasmsSingle-nucleotide polymorphismBiologyPolymorphism Single NucleotideArticle03 medical and health sciencesBreast cancerbreast cancerMeta-Analysis as TopicSDG 3 - Good Health and Well-beingInternal medicineexpressionGeneticsmedicineGenetic predispositionHumansfollow upGenetic Predisposition to Diseasehumanchromosome 1gene030304 developmental biologyCase-control studyCancernucleotide sequencemedicine.diseasechromosome 2pGenetic LociCase-Control Studiescommon variantGenome-Wide Association Studygenetic susceptibilityNature Genetics
researchProduct

Fertility protection: complications of surgery and results of removal and transplantation of ovarian tissue

2017

Fertility-preserving measures are becoming important for patients receiving oncological treatment. One method involves cryopreservation of ovarian tissue and transplanting it when treatment is completed. We report complications resulting from surgical and fertility medicine, and the results of procedures for the removal and transplantation of ovarian tissue carried out within the FertiProtekt network. A survey using a structured questionnaire was conducted among the FertiProtekt network centres between November 2015 and June 2016. The analysis included surgical techniques used to remove and transplant ovarian tissue, surgical complications and results. Laparoscopic removal and transplantati…

medicine.medical_specialtymedia_common.quotation_subjectFertilityOvaryMenstruation03 medical and health sciencesGynecologic Surgical Procedures0302 clinical medicinemedicineHumansFertility preservation610 Medicine & healthLaparoscopyOncofertilitymedia_common030219 obstetrics & reproductive medicinemedicine.diagnostic_testbusiness.industryOvaryFertility PreservationObstetrics and GynecologyCancermedicine.diseaseSurgeryTransplantationmedicine.anatomical_structureReproductive Medicine030220 oncology & carcinogenesisFemalebusinessDevelopmental BiologyReproductive BioMedicine Online
researchProduct

Sorafenib (SOR) plus docetaxel (DOC) as first-line therapy in patients with HER2-negative metastatic breast cancer (MBC): A randomized, placebo-contr…

2014

1072 Background: Anti-angiogenic therapy with the monoclonal anti-VEGF antibody Bevacizumab (Bev) in combination with chemotherapy increases overall response rates (ORR) and progression free surviv...

OncologySorafenibCancer Researchmedicine.medical_specialtyChemotherapyBevacizumabbusiness.industrymedicine.medical_treatmentPharmacologyPlacebomedicine.diseaseMetastatic breast cancerOncologyDocetaxelInternal medicineMonoclonalMedicineIn patientbusinessmedicine.drugJournal of Clinical Oncology
researchProduct